600
Participants
Start Date
April 30, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
Transitional Stepped Co-payment Model - Step 1
Step 1 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 25% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
Transitional Stepped Co-payment Model - Step 2
Step 2 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 50% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
Transitional Stepped Co-payment Model - Step 3
Step 3 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 75% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
Transitional Stepped Co-payment Model - Step 4
Step 4 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 100% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
Dalhousie University, Halifax
Dalhousie University
OTHER
Canadian Center for Vaccinology
OTHER
Canadian Immunization Research Network
NETWORK